Sun Pharma anticipates high single-digit top line growth in current fiscal: Dilip Shanghvi
New Delhi: Sun Pharmaceutical Industries, a leading pharmaceutical company, anticipates achieving a robust single-digit top line increase in revenue for the current fiscal, as stated by Managing Director Dilip Shanghvi.
In FY24, the Mumbai-headquartered company disclosed a consolidated total revenue from operations at Rs 48,497 crore, compared to Rs 43,886 crore in FY23.
"We expect high single-digit consolidated top line growth for FY25. All our businesses are positioned for growth," Shanghvi said in an analyst call.
Read also: Sun Pharma new plant inaugurated in Bangladesh
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd